臨床試験市場における AI – 2030年までの世界予測

Report Overview

The AI in clinical trials market is projected to reach USD 2.74 billion by 2030 from USD 1.35 billion in 2024, at a CAGR of 12.4% from 2024 to 2030.

臨床試験におけるAI市場は、2024 年の 13 億 5,000 万米ドルから 2030 年までに 27 億 4,000 万米ドルに達し、2024 年から 2030 年までの CAGR は 12.4% になると予測されています。

The growing demand for improvements in effectiveness, recruitment of patients in a shorter duration, and accurate analysis of data is the key factor fuelling the market for AI in clinical trials. Solutions powered by AI assist in shortening the duration of various phases of the trial and also in improving patient retention levels using predictive modelling and engagement strategies. In addition, the increase in use of wearables and EMR systems facilitates monitoring at every stage of the course, hence reinforcing the application of AI in trials. Nevertheless, a few obstacles including regulatory norms, prohibitively high cost of implementation and fears of data breach act as constraints hindering the full-scale use of AI in clinical trials.

“Infectious diseases had the fastest growth rate in the AI in clinical trials market during the forecast period, by indication.”

In the sector of conducting clinical studies with the application of AI technologies, it is likely that among all indications infectious diseases will experience the most rapid growth. Such development is very fast owing to the global appeal for quicker and better solutions against disease outbreaks such as the pandemic. AI speed up the patient enrolment process, enhance forecasting, better structure the trials all of which help to deal with fast spreading viruses in a common sense. There has been a significant rise in the use of advanced technologies especially AI owing to the increased campaigns of fighting infectious diseases.

“By end user, the pharmaceutical & biopharma companies to account for largest market share in 2023.”

By end user, AI in clinical trials market is bifurcated into pharmaceutical & biopharma companies, research institutes & labs, healthcare providers, contract research organizations, and medical device manufacturers. The majority of the market share to be occupied by pharmaceutical & biopharma companies’ segment. This is due to the great extent of research and development expenditure, which in turn raises the application of AI for faster drug development processes, better clinical trial designs as well as enhanced patient recruitment for the companies. Such AI systems are designed for such firms to help in a complex analysis of large data sets, quicken the introduction of products into the market, and control the ever-increasing costs which are very essential in winning the competition in the case of the pharmaceutical sector.

“Asia Pacific is estimated to register the highest CAGR over the forecast period.”

The AI in clinical trials market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific AI in clinical trials market is projected to register highest CAGR during the forecast period. The Asia Pacific is benefiting from the fast-developing healthcare infrastructure, advances in AI technologies and expansion of clinical research. With countries such as China, India and Japan encouraging the use of AI in healthcare to facilitate large and varied populations and organize clinical trials more efficiently. Furthermore, owing to the favourable government policies, increasing proliferations of contract research organizations (CROs) and cheaper operation costs in the market relative to the Western regions, many multinational pharmaceutical companies are making it their business to invest in AI clinical trials within the region.

Breakdown of supply-side primary interviews by company type, designation, and region:

• By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
• By Designation: Managers (40%), Directors (35%), and Others (25%)
• By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)

List of Companies Profiled in the Report:

o               IQVIA Inc. (US)

o               Saama. (US)

o               Dassault Systèmes (Medidata) (France)

o               Phesi (US)

o               PathAI, Inc. (US)

o               Unlearn.ai, Inc. (US)

o               Deep6.ai (US)

o               Microsoft (US)

o               IBM (US)

o               NVIDIA Corporation (US)

o               Insilico Medicine (US)

o               ConcertAI. (US)

o               AiCure. (US)

o               Median Technologies. (France)

o               Lantern Pharma Inc. (US)

o               Citeline, a Norstella Company (US)

o               Tempus AI, Inc. (US)

o               TriNetX, LLC (US)

o               ReviveMed Inc. (US)

o               Euretos. (US)

o               VeriSIM Life. (US)

o               Triomics (US)

o               Ardigen (Poland)

o               QuantHealth Ltd. US)

o               DEEP GENOMICS. (Canada)

Research Coverage:

This research report categorizes the AI in clinical trials market by offerings (end-to-end solutions, niche solutions, technology providers and services), function (patient recruitment, trial design optimization, data management & quality control, adverse event prediction & detection, drug repurposing, and regulatory compliance), phase (phase I, phase II, phase III and phase IV), deployment mode (cloud-based solutions, and on-premise solutions), indication (oncology, neurological diseases, cardiovascular diseases, metabolic diseases, infectious diseases, immunology diseases, and others (gastrointestinal, respiratory & reproductive), technology (machine learning, NLP, computer vision, robotic process automation, and others), application (biomarkers, cell & gene therapy, regenerative medicine, and medical devices & diagnostics), end user (pharmaceutical & biotechnology companies, research institutes & labs, healthcare providers, contract research organizations (CROs), and medical device manufacturers) and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in clinical trials market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the AI in clinical trials market. Competitive analysis of upcoming startups in the AI in clinical trials market ecosystem is covered in this report.

Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall AI in clinical trials market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers: (Growing demand for faster and more efficient drug development), restraints (High costs associated with implementing AI solutions), opportunities (Increased focus on precision medicine), and challenges (Complexity of integrating AI into traditional clinical trial frameworks) influencing the growth of the AI in clinical trials market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in clinical trials market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the AI in clinical trials market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the AI in clinical trials market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as IQVIA Inc. (US), Dassault Systèmes (Medidata) (France), Tempus AI, Inc. (US), Insilico Medicine (US),  ConcertAI. (US), AiCure. (US) PathAI, Inc. (US), etc. among others in AI in clinical trials market

Table of Contents

1               INTRODUCTION              33

1.1           STUDY OBJECTIVES       33

1.2           MARKET DEFINITION   33

1.3           STUDY SCOPE   34

1.3.1        SEGMENTS CONSIDERED             34

1.3.2        INCLUSIONS & EXCLUSIONS       35

1.3.3        YEARS CONSIDERED      37

1.3.4        CURRENCY CONSIDERED            37

1.4           STAKEHOLDERS               37

2               RESEARCH METHODOLOGY       39

2.1           RESEARCH DATA              39

2.1.1        SECONDARY DATA          40

2.1.1.1    Key sources for secondary data          40

2.1.1.2    Key data from secondary sources       41

2.1.2        PRIMARY DATA 41

2.1.2.1    Key sources for primary data              42

2.1.2.2    Objectives of primary research           42

2.1.2.3    Key data from primary sources           43

2.1.2.4    Key insights from primary experts     44

2.2           MARKET SIZE ESTIMATION         45

2.2.1        SUPPLY-SIDE REVENUE SHARE ANALYSIS             45

2.2.2        PARENT MARKET APPROACH    45

2.2.3        COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS      45

2.2.4        MARKET SEGMENT ASSESSMENT             46

2.2.5        GEOGRAPHIC MARKET ASSESSMENT     47

2.3           DATA TRIANGULATION                49

2.4           MARKET SHARE ESTIMATION    50

2.5           STUDY ASSUMPTIONS  50

2.6           RESEARCH LIMITATIONS             50

2.6.1        METHODOLOGY-RELATED LIMITATIONS           50

2.6.2        SCOPE-RELATED LIMITATIONS                 50

2.7           RISK ASSESSMENT           51

3               EXECUTIVE SUMMARY  52

4               PREMIUM INSIGHTS       59

4.1           AI IN CLINICAL TRIALS MARKET OVERVIEW       59

4.2           AI IN CLINICAL TRIALS MARKET, BY REGION      60

4.3           NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER AND COUNTRY           61

4.4           AI IN CLINICAL TRIALS MARKET: GEOGRAPHICAL SNAPSHOT          62

4.5           AI IN CLINICAL TRIALS MARKET: DEVELOPED VS. EMERGING MARKETS    63

5               MARKET OVERVIEW       64

5.1           INTRODUCTION              64

5.2           MARKET DYNAMICS       64

5.3           MARKET DYNAMICS       65

5.3.1        DRIVERS               65

5.3.1.1    Increasing demand for personalized treatments              65

5.3.1.2    Support for decentralized and global trials       67

5.3.1.3    Regulatory compliance and ethical considerations          67

5.3.1.4    Automated document review for better regulatory compliance                 68

5.3.1.5    Focus on real-time data management and analysis         68

5.3.2        RESTRAINTS      69

5.3.2.1    Data privacy and security concerns   69

5.3.2.2    Integration challenges with legacy systems and resistance from healthcare professionals      70

5.3.2.3    High implementation cost and need for skilled AI professionals                 71

5.3.3        OPPORTUNITIES              71

5.3.3.1    Use of predictive analytics in clinical trials       71

5.3.3.2    Development of virtual control arms for faster trials      72

5.3.3.3    Integrating natural language processing into clinical trials for data extraction      73

5.3.4        CHALLENGES    73

5.3.4.1    Addressing algorithm bias and fairness             73

5.3.4.2    Insufficient technical expertise in AI-based solutions    74

5.4           INDUSTRY TRENDS         74

5.4.1        INCREASING ADOPTION OF DECENTRALIZED CLINICAL TRIALS             74

5.4.2        RISING FOCUS ON AI-POWERED PATIENT RECRUITMENT AND RETENTION             74

5.5           ECOSYSTEM ANALYSIS  75

5.6           CASE STUDY ANALYSIS 75

5.6.1        AI-POWERED APPROACH TO OVERCOME CHALLENGES IN IPF DRUG DEVELOPMENT     75

5.6.2        REVOLUTIONIZING CLINICAL TRIAL ENROLLMENT WITH ADVANCED MATCHING NETWORKS          76

5.6.3        BREAKTHROUGH IN CANCER TREATMENT WITH FDA APPROVAL FOR PHASE 1 TRIALS               77

5.7           VALUE CHAIN ANALYSIS               77

5.8           PORTER’S FIVE FORCES ANALYSIS            79

5.8.1        BARGAINING POWER OF SUPPLIERS       80

5.8.2        BARGAINING POWER OF BUYERS             80

5.8.3        THREAT OF SUBSTITUTES          81

5.8.4        THREAT OF NEW ENTRANTS      81

5.8.5        INTENSITY OF COMPETITIVE RIVALRY 81

5.9           KEY STAKEHOLDERS & BUYING CRITERIA            82

5.9.1        KEY STAKEHOLDERS IN BUYING PROCESS           82

5.9.2        KEY BUYING CRITERIA  83

5.10         REGULATORY LANDSCAPE         83

5.10.1      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             84

5.10.2      REGULATORY FRAMEWORK       84

5.11         PATENT ANALYSIS          87

5.11.1      PATENT PUBLICATION TRENDS FOR AI IN CLINICAL TRIALS 87

5.11.2      JURISDICTION AND TOP APPLICANT ANALYSIS                 88

5.12         TECHNOLOGY ANALYSIS             90

5.12.1      KEY TECHNOLOGIES     90

5.12.1.1  Machine learning 90

5.12.1.2  Natural language processing               90

5.12.1.3  Computer vision   90

5.12.2      COMPLEMENTARY TECHNOLOGIES       90

5.12.2.1  Internet of things 90

5.12.2.2  Cloud computing  90

5.12.3      ADJACENT TECHNOLOGIES       91

5.12.3.1  Advanced genomics              91

5.13         PRICING ANALYSIS          91

5.13.1      INDICATIVE PRICE OF KEY AI SOFTWARE, BY KEY PLAYER, 2023      91

5.13.2      INDICATIVE PRICE TREND OF KEY AI SOFTWARE, BY REGION,  2022–2024        92

5.14         KEY CONFERENCES & EVENTS, 2024–2025              92

5.15         TRENDS AND DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS            93

5.16         UNMET NEEDS AND END-USER EXPECTATIONS                 94

5.16.1      UNMET NEEDS 94

5.16.2      END-USER EXPECTATIONS         95

5.17         INVESTMENT & FUNDING SCENARIO     95

5.18         IMPACT OF AI/GEN AI ON AI IN CLINICAL TRIALS MARKET               96

5.18.1      KEY USE CASES 97

5.18.2      IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS              97

5.18.2.1  Case study              97

5.18.2.2  Clinical trials market            98

5.18.2.3  eClinical solutions market   98

5.18.2.4  AI in biotechnology market 99

5.18.3      USERS READINESS AND IMPACT ASSESSMENT   99

5.18.3.1  User readiness       99

5.18.3.1.1                Pharmaceutical & biopharmaceutical companies                 99

5.18.3.1.2                Contract research organizations         99

5.18.3.2  Impact assessment                99

5.18.3.2.1                User A: Healthcare providers              99

5.18.3.2.2                User B: Research institutes & laboratories       100

6               AI IN CLINICAL TRIALS MARKET, BY OFFERING 101

6.1           INTRODUCTION              102

6.2           END-TO-END SOLUTIONS           102

6.2.1        COST-EFFECTIVENESS, IMPROVED EFFICIENCY, AND REDUCED HUMAN ERRORS TO DRIVE ADOPTION IN CLINICAL TRIALS 102

6.3           NICHE SOLUTIONS         103

6.3.1        HIGH FAILURE RATES OF CLINICAL TRIALS AND NEED FOR STREAMLINED PROCESSES TO FUEL MARKET GROWTH                 103

6.4           TECHNOLOGY PROVIDERS         104

6.4.1        NEED TO ACCELERATE DRUG DEVELOPMENT PROCESSES AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH 104

6.5           SERVICES             105

6.5.1        CONSULTING SERVICES                106

6.5.1.1    Consulting services to optimize trial design, enhance patient recruitment, and improve data management   106

6.5.2        IMPLEMENTATION SERVICES & ONGOING IT SUPPORT                 107

6.5.2.1    Need for smooth integration and optimization of AI technologies to boost segment growth     107

6.5.3        TRAINING & EDUCATION SERVICES        108

6.5.3.1    Need for skilled talent for managing complex AI systems to augment segment growth    108

6.5.4        POST-SALES & MAINTENANCE SERVICES              109

6.5.4.1    Development of complex AI systems and need for continuous improvement in AI algorithms to drive segment growth                109

7               AI IN CLINICAL TRIALS MARKET, BY FUNCTION                 111

7.1           INTRODUCTION              112

7.2           PATIENT RECRUITMENT              112

7.2.1        PATIENT IDENTIFICATION & SCREENING            114

7.2.1.1    Reduced patient screening time and better accuracy than human clinicians to drive market    114

7.2.2        PATIENT ENGAGEMENT & RETENTION 115

7.2.2.1    Better personalized communication and support for clinical trials to propel market growth      115

7.2.3        SITE OPTIMIZATION      116

7.2.3.1    Cost-effective and improved participant recruitment and retention to fuel segment growth       116

7.3           TRIAL DESIGN OPTIMIZATION 117

7.3.1        WORKFLOW MANAGEMENT       118

7.3.1.1    Effective real-time tracking, automated reporting, and milestone monitoring to spur segment growth  118

7.3.2        PREDICTIVE MODELING              119

7.3.2.1    Ability to optimize trial design, predict risks, and identify effective treatment protocols to drive segment                119

7.3.3        RISK MANAGEMENT       120

7.3.3.1    AI-driven solutions for risk prediction to improve patient safety and data integrity 120

7.4           DATA MANAGEMENT & QUALITY CONTROL      121

7.4.1        FOCUS ON MAINTAINING DATA ACCURACY AND INTEGRITY IN CLINICAL TRIALS TO BOOST ADOPTION                 121

7.5           ADVERSE EVENT PREDICTION & DETECTION    122

7.5.1        MITIGATING RISKS AND HARNESSING AI-DRIVEN ADVERSE EVENT DETECTION TO SPUR MARKET GROWTH                 122

7.6           DRUG REPURPOSING    123

7.6.1        DRUG REPURPOSING TO VALIDATE HYPOTHESES AGAINST REAL-TIME PATIENT DATA IN RARE DISEASES                 123

7.7           REGULATORY COMPLIANCE      124

7.7.1        COMPLEXITY OF GLOBAL REGULATORY ENVIRONMENTS AND NEED FOR FASTER DRUG APPROVALS TO AID MARKET GROWTH 124

8               AI IN CLINICAL TRIALS MARKET, BY PHASE         126

8.1           INTRODUCTION              127

8.2           PHASE I CLINICAL TRIALS            127

8.2.1        FASTER PATIENT IDENTIFICATION AND RECRUITMENT TO PROPEL ADOPTION OF AI    127

8.3           PHASE II CLINICAL TRIALS          128

8.3.1        NEED FOR ACCURATE PREDICTION OF OPTIMAL DOSAGE IN PHASE II TRIALS TO BOOST USE OF AI           128

8.4           PHASE III CLINICAL TRIALS         129

8.4.1        NEED TO CHECK DRUG EFFICACY AND MONITOR ADVERSE REACTIONS TO AUGMENT MARKET GROWTH                 129

8.5           PHASE IV CLINICAL TRIALS         130

8.5.1        AI TO ASSESS SAFETY AND LONG-TERM OUTCOMES OF TREATMENT IN LARGER PATIENT POPULATION UNDER PHASE IV TRIALS             130

9               AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE   132

9.1           INTRODUCTION              133

9.2           CLOUD-BASED SOLUTIONS        133

9.2.1        PUBLIC CLOUD-BASED SOLUTIONS       135

9.2.1.1    Reduced need for costly on-premises infrastructure and better regulatory compliance to fuel adoption             135

9.2.2        PRIVATE CLOUD-BASED SOLUTIONS     136

9.2.2.1    Better security and personalization for sensitive data to propel segment growth    136

9.2.3        MULTI CLOUD-BASED SOLUTIONS         137

9.2.3.1    Use of advanced predictive modeling for patient recruitment and site performance optimization to drive market                137

9.2.4        HYBRID CLOUD-BASED SOLUTIONS       138

9.2.4.1    Better flexibility in data management to reduce resource requirements in clinical trials              138

9.3           ON-PREMISES SOLUTIONS          139

9.3.1        ON-PREMISES SOLUTIONS TO OFFER SECURE ENVIRONMENT FOR MANAGING SENSITIVE DATA AND RUNNING COMPLEX ALGORITHMS         139

10            AI IN CLINICAL TRIALS MARKET, BY INDICATION                 140

10.1         INTRODUCTION              141

10.2         ONCOLOGY        141

10.2.1      HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE DRUGS TO DRIVE SEGMENT GROWTH           141

10.3         NEUROLOGICAL DISEASES         142

10.3.1      COMPLEXITY OF NEUROGENERATIVE DISORDERS AND SHORTAGE OF DRUGS FOR PARKINSON’S DISEASE TO SPUR MARKET GROWTH          142

10.4         CARDIOVASCULAR DISEASES    144

10.4.1      RISING DEMAND FOR NOVEL CARDIOVASCULAR DRUGS TO DRIVE SEGMENT      144

10.5         METABOLIC DISEASES  145

10.5.1      RISING PREVALENCE OF DIABETES AND OBESITY TO SUPPORT MARKET GROWTH     145

10.6         INFECTIOUS DISEASES 146

10.6.1      RECENT EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITIES FOR INFECTIOUS DISEASES      146

10.7         IMMUNOLOGY DISEASES             147

10.7.1      GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH           147

10.8         OTHER DISEASES             148

11            AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY                 150

11.1         INTRODUCTION              151

11.2         MACHINE LEARNING     151

11.2.1      DEEP LEARNING               153

11.2.1.1  Reduced chance of errors in clinical trials and enhanced data consistency to augment segment growth          153

11.2.2      SUPERVISED LEARNING                155

11.2.2.1  Supervised learning to focus on effective patient stratification, disease progression prediction, and biomarker identification       155

11.2.3      UNSUPERVISED LEARNING         156

11.2.3.1  Effective handling of complex and unstructured datasets to aid adoption in trial design and execution               156

11.2.4      REINFORCEMENT LEARNING     157

11.2.4.1  Dynamic learning capabilities to aid adoption in personalized medicine and precision oncology       157

11.2.5      OTHER MACHINE LEARNING TECHNOLOGIES  158

11.3         NATURAL LANGUAGE PROCESSING       159

11.3.1      ABUNDANCE OF UNSTRUCTURED DATA IN CLINICAL RESEARCH TO PROPEL GROWTH IN TRIAL MANAGEMENT                 159

11.4         COMPUTER VISION        160

11.4.1      RISING NEED FOR REPRODUCIBLE ANALYSIS IN CLINICAL ENDPOINTS TO DRIVE MARKET           160

11.5         ROBOTIC PROCESS AUTOMATION          161

11.5.1      ROBOTIC PROCESS AUTOMATION TO ENHANCE OPERATIONAL EFFICIENCY

BY AUTOMATING ADMINISTRATIVE WORKFLOWS          161

11.6         OTHER TECHNOLOGIES               162

12            AI IN CLINICAL TRIALS MARKET, BY APPLICATION                 163

12.1         INTRODUCTION              164

12.2         BIOMARKERS     164

12.2.1      INCREASING INVESTMENTS IN AI-BASED INNOVATION TO AID DEVELOPMENT OF PERSONALIZED HEALTHCARE SOLUTIONS        164

12.3         CELL & GENE THERAPY 165

12.3.1      HIGH PREVALENCE OF GENETIC DISORDERS AND TECHNOLOGICAL ADVANCEMENTS IN CAR-T THERAPIES TO DRIVE GROWTH               165

12.4         REGENERATIVE MEDICINES       166

12.4.1      INCREASED NEED FOR PRECISE MONITORING AND ADVANCEMENTS IN STEM CELL RESEARCH TO SPUR MARKET GROWTH             166

12.5         MEDICAL DEVICES & DIAGNOSTICS       167

12.5.1      NEED FOR REAL-TIME MONITORING AND REMOTE DATA ACQUISITION DURING TRIALS TO ACCELERATE MARKET GROWTH             167

13            AI IN CLINICAL TRIALS MARKET, BY END USER 169

13.1         INTRODUCTION              170

13.2         PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES       170

13.2.1      HIGH R&D INVESTMENTS AND INCREASED REGULATORY COMPLIANCE TO AUGMENT MARKET GROWTH                 170

13.3         RESEARCH INSTITUTES & LABORATORIES           171

13.3.1      INCREASED GOVERNMENT GRANTS AND COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO SUPPORT MARKET GROWTH     171

13.4         HEALTHCARE PROVIDERS           172

13.4.1      ADVANCEMENTS IN PRECISION MEDICINES AND NEED FOR REAL-WORLD EVIDENCE IN CLINICAL RESEARCH TO DRIVE MARKET 172

13.5         CONTRACT RESEARCH ORGANIZATIONS             173

13.5.1      RISING DEMAND FOR OUTSOURCING CLINICAL TRIAL ACTIVITIES  BY PHARMACEUTICAL COMPANIES TO AID MARKET GROWTH          173

13.6         MEDICAL DEVICE MANUFACTURERS     175

13.6.1      DEMAND FOR AI-DRIVEN DIAGNOSTICS AND MONITORING DEVICES FOR REMOTE CARE TO PROPEL MARKET GROWTH          175

14            AI IN CLINICAL TRIALS MARKET, BY REGION      176

14.1         INTRODUCTION              177

14.2         NORTH AMERICA             177

14.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 178

14.2.2      US           183

14.2.2.1  US to dominate North American AI in clinical trials market during study period              183

14.2.3      CANADA               188

14.2.3.1  Rising need for data standardization and increasing health expenditure to support market growth              188

14.3         EUROPE               192

14.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      192

14.3.2      UK          197

14.3.2.1  High R&D investment by government organizations to augment market growth       197

14.3.3      GERMANY           202

14.3.3.1  Increased focus on research activities and strategic developments

by pharma & biotech companies to drive market             202

14.3.4      FRANCE                206

14.3.4.1  Strong government support and focus on domestic drug research

to propel market growth    206

14.3.5      ITALY    211

14.3.5.1  Increased R&D investments from pharmaceutical companies and reduced time for drug approvals to fuel market growth 211

14.3.6      SPAIN    215

14.3.6.1  Increased technological investments by private organizations and integrated healthcare systems to spur market growth    215

14.3.7      REST OF EUROPE             219

14.4         ASIA PACIFIC     223

14.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 223

14.4.2      JAPAN   229

14.4.2.1  Well-established clinical trial infrastructure and advanced biomedical research to support market growth                229

14.4.3      CHINA  233

14.4.3.1  Low cost of clinical trials and availability of treatment-naïve population to propel market growth  233

14.4.4      INDIA    238

14.4.4.1  Favorable government policies and high R&D expenditure by Indian pharmaceutical companies to spur market growth              238

14.4.5      REST OF ASIA PACIFIC   242

14.5         LATIN AMERICA                246

14.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 246

14.5.2      BRAZIL 251

14.5.2.1  Increasing governmental support for innovation and growing biotechnology sector to drive market                 251

14.5.3      MEXICO                256

14.5.3.1  Strong technological and research capabilities in AI applications to fuel market growth           256

14.5.4      REST OF LATIN AMERICA             260

14.6         MIDDLE EAST & AFRICA                264

14.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 265

14.6.2      GCC COUNTRIES              269

14.6.2.1  Technological innovations and focus on precision medicines to augment market growth      269

14.6.3      REST OF MIDDLE EAST & AFRICA             274

15            COMPETITIVE LANDSCAPE         279

15.1         INTRODUCTION              279

15.2         KEY PLAYER STRATEGY/RIGHT TO WIN                279

15.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET         280

15.3         REVENUE ANALYSIS, 2019–2023  281

15.4         MARKET SHARE ANALYSIS, 2023                 282

15.4.1      RANKING OF KEY MARKET PLAYERS       284

15.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023                 285

15.5.1      STARS   285

15.5.2      EMERGING LEADERS     285

15.5.3      PERVASIVE PLAYERS      285

15.5.4      PARTICIPANTS 285

15.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2023         287

15.5.5.1  Company footprint               287

15.5.5.2  Region footprint   288

15.5.5.3  Offering footprint 289

15.5.5.4  Function footprint                290

15.5.5.5  End-user footprint                291

15.6         COMPANY EVALUATION QUADRANT: STARTUP/SMES, 2023        292

15.6.1      PROGRESSIVE COMPANIES         292

15.6.2      RESPONSIVE COMPANIES            292

15.6.3      DYNAMIC COMPANIES  292

15.6.4      STARTING BLOCKS         292

15.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023                 294

15.7         COMPANY EVALUATION & FINANCIAL METRICS                 296

15.8         BRAND/PRODUCT COMPARISON             297

15.9         COMPETITIVE SCENARIO             298

15.9.1      PRODUCT/SERVICE/SOLUTION LAUNCHES        298

15.9.2      DEALS  299

15.9.3      OTHER DEVELOPMENTS              300

16            COMPANY PROFILES      301

16.1         KEY PLAYERS     301

16.1.1      IQVIA INC.           301

16.1.1.1  Products/Services/Solutions offered 303

16.1.1.2  Recent developments           303

16.1.1.2.1                Solution launches 303

16.1.1.2.2                Deals      304

16.1.1.3  MnM view              304

16.1.1.3.1                Right to win           304

16.1.1.3.2                Strategic choices   305

16.1.1.3.3                Weaknesses & competitive threats     305

16.1.2      DASSAULT SYSTÈMES (MEDIDATA)        306

16.1.2.1  Business overview 306

16.1.2.2  Products/Services/Solutions offered 307

16.1.2.3  Recent developments           307

16.1.2.3.1                Solution launches 307

16.1.2.3.2                Deals      308

16.1.2.4  MnM view              308

16.1.2.4.1                Right to win           308

16.1.2.4.2                Strategic choices   308

16.1.2.4.3                Weaknesses & competitive threats     308

16.1.3      INSILICO MEDICINE       309

16.1.3.1  Business overview 309

16.1.3.2  Products/Services/Solutions offered 309

16.1.3.3  Recent developments           310

16.1.3.3.1                Other developments             310

16.1.3.4  MnM view              310

16.1.3.4.1                Right to win           310

16.1.3.4.2                Strategic choices   310

16.1.3.4.3                Weaknesses & competitive threats     311

16.1.4      TEMPUS AI, INC.               312

16.1.4.1  Business overview 312

16.1.4.2  Products/Services/Solutions offered 312

16.1.4.3  Recent developments           313

16.1.4.3.1                Solution launches 313

16.1.4.3.2                Deals      313

16.1.4.3.3                Other developments             315

16.1.4.4  MnM view              315

16.1.4.4.1                Right to win           315

16.1.4.4.2                Strategic choices   315

16.1.4.4.3                Weaknesses & competitive threats     315

16.1.5      NVIDIA CORPORATION 316

16.1.5.1  Business overview 316

16.1.5.2  Products/Services/Solutions offered 317

16.1.5.3  Recent developments           318

16.1.5.3.1                Product and service launches             318

16.1.5.3.2                Deals      319

16.1.5.4  MnM view              321

16.1.5.4.1                Right to win           321

16.1.5.4.2                Strategic choices   321

16.1.5.4.3                Weaknesses & competitive threats     321

16.1.6      SAAMA 322

16.1.6.1  Business overview 322

16.1.6.2  Products/Services/Solutions offered 322

16.1.6.3  Recent developments           323

16.1.6.3.1                Solution launches 323

16.1.6.3.2                Deals      324

16.1.7      PHESI    325

16.1.7.1  Business overview 325

16.1.7.2  Products/Services/Solutions offered 325

16.1.7.3  Recent developments           326

16.1.7.3.1                Solution launches 326

16.1.7.3.2                Deals      327

16.1.8      PATHAI, INC.     328

16.1.8.1  Business overview 328

16.1.8.2  Products/Services/Solutions offered 328

16.1.9      UNLEARN.AI, INC.            329

16.1.9.1  Business overview 329

16.1.9.2  Products/Services/Solutions offered 329

16.1.9.3  Recent developments           331

16.1.9.3.1                Solution launches 331

16.1.9.3.2                Deals      331

16.1.9.3.3                Other developments             332

16.1.10   DEEP6.AI              333

16.1.10.1                 Business overview 333

16.1.10.2                 Products/Services/Solutions offered 333

16.1.10.3                 Recent developments           334

16.1.10.3.1             Solution launch     334

16.1.10.3.2             Deals      334

16.1.11   MICROSOFT       335

16.1.11.1                 Business overview 335

16.1.11.2                 Products/Services/Solutions offered 337

16.1.11.3                 Recent developments           337

16.1.12   IBM        340

16.1.12.1                 Business overview 340

16.1.12.2                 Products/Services/Solutions offered 341

16.1.12.3                 Recent developments           342

16.1.12.3.1             Deals      342

16.1.13   CONCERTAI       343

16.1.13.1                 Business overview 343

16.1.13.2                 Products/Services/Solutions offered 343

16.1.13.3                 Recent developments           344

16.1.13.3.1             Solution launches 344

16.1.13.3.2             Deals      344

16.1.13.3.3             Other developments             345

16.1.14   AICURE 346

16.1.14.1                 Business overview 346

16.1.14.2                 Products/Services/Solutions offered 346

16.1.14.3                 Recent developments           347

16.1.14.3.1             Service launches   347

16.1.14.3.2             Deals      347

16.1.15   MEDIAN TECHNOLOGIES            349

16.1.15.1                 Business overview 349

16.1.15.2                 Products/Services/Solutions offered 350

16.1.16   LANTERN PHARMA INC.                351

16.1.16.1                 Business overview 351

16.1.16.2                 Products/Services/Solutions offered 351

16.1.16.3                 Recent developments           352

16.1.16.3.1             Deals      352

16.1.17   CITELINE, A NORSTELLA COMPANY       353

16.1.17.1                 Business overview 353

16.1.17.2                 Products/Services/Solutions offered 353

16.1.17.3                 Recent developments           354

16.1.17.3.1             Solution launches 354

16.1.17.3.2             Deals      354

16.1.18   TRINETX, LLC    355

16.1.18.1                 Business overview 355

16.1.18.2                 Products/Services/Solutions offered 355

16.1.18.3                 Recent developments           356

16.1.18.3.1             Deals      356

16.2         OTHER PLAYERS              357

16.2.1      REVIVEMED INC.              357

16.2.2      EURETOS             358

16.2.3      VERISIM LIFE     359

16.2.4      TRIOMICS            359

16.2.5      ARDIGEN             360

16.2.6      QUANTHEALTH LTD.    361

16.2.7      DEEP GENOMICS             362

17            APPENDIX           363

17.1         DISCUSSION GUIDE        363

17.2         KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL                369

17.3         CUSTOMIZATION OPTIONS        371

17.4         RELATED REPORTS         371

17.5         AUTHOR DETAILS           372

LIST OF TABLES

TABLE 1                AI IN CLINICAL TRIALS MARKET: INCLUSIONS & EXCLUSIONS      35

TABLE 2                AI IN CLINICAL TRIALS MARKET: STUDY ASSUMPTIONS  50

TABLE 3                AI IN CLINICAL TRIALS MARKET: RISK ASSESSMENT     51

TABLE 4                AI IN CLINICAL TRIALS MARKET: IMPACT ANALYSIS            65

TABLE 5                CASE STUDY 1: AI-POWERED APPROACH TO OVERCOME CHALLENGES IN

IPF DRUG DEVELOPMENT           75

TABLE 6                CASE STUDY 2: REVOLUTIONIZING CLINICAL TRIAL ENROLLMENT WITH

ADVANCED MATCHING NETWORKS       76

TABLE 7                CASE STUDY 3: BREAKTHROUGH IN CANCER TREATMENT WITH FDA APPROVAL FOR PHASE 1 TRIALS                 77

TABLE 8                AI IN CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES                80

TABLE 9                INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE

END USERS (%) 82

TABLE 10              KEY BUYING CRITERIA FOR TOP THREE END USERS   83

TABLE 11              LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  84

TABLE 12              NORTH AMERICA: REGULATORY FRAMEWORK                 84

TABLE 13              EUROPE: REGULATORY FRAMEWORK    85

TABLE 14              ASIA PACIFIC: REGULATORY FRAMEWORK                 86

TABLE 15              MIDDLE EAST & AFRICA: REGULATORY FRAMEWORK     86

TABLE 16              LATIN AMERICA: REGULATORY FRAMEWORK                 87

TABLE 17              AI IN CLINICAL TRIALS MARKET: LIST OF PATENTS/PATENT

APPLICATIONS, 2023–2024             89

TABLE 18              INDICATIVE PRICE OF KEY AI SOFTWARE, BY KEY PLAYER, 2023             91

TABLE 19              INDICATIVE PRICE TREND OF KEY AI SOFTWARE, BY REGION, 2022–2024           92

TABLE 20              AI IN CLINICAL TRIALS MARKET: KEY CONFERENCES & EVENTS,

JANUARY 2024–DECEMBER 2025 92

TABLE 21              AI IN CLINICAL TRIALS MARKET: UNMET NEEDS                 94

TABLE 22              AI IN CLINICAL TRIALS MARKET: END-USER EXPECTATIONS                95

TABLE 23              AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)            102

TABLE 24              AI IN CLINICAL TRIALS MARKET FOR END-TO-END SOLUTIONS,

BY COUNTRY,  2022–2030 (USD MILLION)            103

TABLE 25              AI IN CLINICAL TRIALS MARKET FOR NICHE SOLUTIONS, BY COUNTRY,

2022–2030 (USD MILLION)            104

TABLE 26              AI IN CLINICAL TRIALS MARKET FOR TECHNOLOGY PROVIDERS, BY COUNTRY,  2022–2030 (USD MILLION)            105

TABLE 27              AI IN CLINICAL TRIALS MARKET FOR SERVICES, BY COUNTRY,

2022–2030 (USD MILLION)            106

TABLE 28             CONSULTING SERVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)            107

TABLE 29              IMPLEMENTATION SERVICES & OUTGOING IT SUPPORT MARKET,

BY COUNTRY,  2022–2030 (USD MILLION)            108

TABLE 30              TRAINING & EDUCATION SERVICES MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            109

TABLE 31              POST-SALES & MAINTENANCE SERVICES MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            110

TABLE 32              AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)            112

TABLE 33              AI IN CLINICAL TRIALS MARKET FOR PATIENT RECRUITMENT, BY TYPE,

2022–2030 (USD MILLION)            113

TABLE 34              AI IN CLINICAL TRIALS MARKET FOR PATIENT RECRUITMENT, BY COUNTRY,

2022–2030 (USD MILLION)            113

TABLE 35              PATIENT IDENTIFICATION & SCREENING MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            114

TABLE 36              PATIENT ENGAGEMENT & RETENTION MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            115

TABLE 37              SITE OPTIMIZATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION)            116

TABLE 38              AI IN CLINICAL TRIALS MARKET FOR TRIAL DESIGN OPTIMIZATION, BY TYPE,  2022–2030 (USD MILLION)                 117

TABLE 39              AI IN CLINICAL TRIALS MARKET FOR TRIAL DESIGN OPTIMIZATION, BY COUNTRY,  2022–2030 (USD MILLION)            118

TABLE 40              AI IN CLINICAL TRIALS MARKET FOR WORKFLOW MANAGEMENT,  BY COUNTRY, 2022–2030 (USD MILLION)            119

TABLE 41              AI IN CLINICAL TRIALS MARKET FOR PREDICTIVE MODELING,  BY COUNTRY,

2022–2030 (USD MILLION)            120

TABLE 42              AI IN CLINICAL TRIALS MARKET FOR RISK MANAGEMENT, BY COUNTRY,

2022–2030 (USD MILLION)            121

TABLE 43              AI IN CLINICAL TRIALS MARKET FOR DATA MANAGEMENT & QUALITY CONTROL,

BY COUNTRY, 2022–2030 (USD MILLION)               122

TABLE 44              AI IN CLINICAL TRIALS MARKET FOR ADVERSE EVENT PREDICTION & DETECTION,  BY COUNTRY, 2022–2030 (USD MILLION) 123

TABLE 45              AI IN CLINICAL TRIALS MARKET FOR DRUG REPURPOSING, BY COUNTRY,

2022–2030 (USD MILLION)            124

TABLE 46              AI IN CLINICAL TRIALS MARKET FOR REGULATORY COMPLIANCE,

BY COUNTRY,  2022–2030 (USD MILLION)            125

TABLE 47              AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)            127

TABLE 48              AI IN PHASE 1 CLINICAL TRIALS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            128

TABLE 49              AI IN PHASE II CLINICAL TRIALS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            129

TABLE 50              AI IN PHASE III CLINICAL TRIALS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            130

TABLE 51              AI IN PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            131

TABLE 52              AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            133

TABLE 53              AI IN CLINICAL TRIALS MARKET FOR CLOUD-BASED SOLUTIONS,

BY TYPE,  2022–2030 (USD MILLION)      134

TABLE 54              AI IN CLINICAL TRIALS MARKET FOR CLOUD-BASED SOLUTIONS,

BY COUNTRY,  2022–2030 (USD MILLION)            134

TABLE 55              PUBLIC CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            135

TABLE 56              PRIVATE CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            136

TABLE 57              MULTI CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            137

TABLE 58              HYBRID CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            138

TABLE 59              AI IN CLINICAL TRIALS MARKET FOR ON-PREMISES SOLUTIONS, BY COUNTRY,  2022–2030 (USD MILLION)            139

TABLE 60              AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)                141

TABLE 61              AI IN CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY,

2022–2030 (USD MILLION)            142

TABLE 62              AI IN CLINICAL TRIALS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY,  2022–2030 (USD MILLION)            143

TABLE 63              AI IN CLINICAL TRIALS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY,  2022–2030 (USD MILLION)            144

TABLE 64              AI IN CLINICAL TRIALS MARKET FOR METABOLIC DISEASES, BY COUNTRY,

2022–2030 (USD MILLION)            145

TABLE 65              AI IN CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,

2022–2030 (USD MILLION)            147

TABLE 66              AI IN CLINICAL TRIALS MARKET FOR IMMUNOLOGY DISEASES, BY COUNTRY,  2022–2030 (USD MILLION)            148

TABLE 67              AI IN CLINICAL TRIALS MARKET FOR OTHER DISEASES, BY COUNTRY,

2022–2030 (USD MILLION)            149

TABLE 68              AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            151

TABLE 69              AI IN CLINICAL TRIALS MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)            152

TABLE 70              AI IN CLINICAL TRIALS MARKET FOR MACHINE LEARNING, BY COUNTRY,

2022–2030 (USD MILLION)            153

TABLE 71              DEEP LEARNING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)       154

TABLE 72              SUPERVISED LEARNING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)            155

TABLE 73              UNSUPERVISED LEARNING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)     156

TABLE 74              REINFORCEMENT LEARNING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)     157

TABLE 75              OTHER MACHINE LEARNING TECHNOLOGIES MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            158

TABLE 76              AI IN CLINICAL TRIALS MARKET FOR NATURAL LANGUAGE PROCESSING,

BY COUNTRY, 2022–2030 (USD MILLION)               159

TABLE 77              AI IN CLINICAL TRIALS MARKET FOR COMPUTER VISION, BY COUNTRY,

2022–2030 (USD MILLION)            160

TABLE 78              AI IN CLINICAL TRIALS MARKET FOR ROBOTIC PROCESS AUTOMATION,

BY COUNTRY, 2022–2030 (USD MILLION)               161

TABLE 79              AI IN CLINICAL TRIALS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,

2022–2030 (USD MILLION)            162

TABLE 80              AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              164

TABLE 81              AI IN CLINICAL TRIALS MARKET FOR BIOMARKERS, BY COUNTRY,

2022–2030 (USD MILLION)            165

TABLE 82              AI IN CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY,

2022–2030 (USD MILLION)            166

TABLE 83              AI IN CLINICAL TRIALS MARKET FOR REGENERATIVE MEDICINES,

BY COUNTRY,  2022–2030 (USD MILLION)            167

TABLE 84              AI IN CLINICAL TRIALS MARKET FOR MEDICAL DEVICES & DIAGNOSTICS,

BY COUNTRY, 2022–2030 (USD MILLION)               168

TABLE 85              AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)            170

TABLE 86              AI IN CLINICAL TRIALS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)     171

TABLE 87              AI IN CLINICAL TRIALS MARKET FOR RESEARCH INSTITUTES & LABORATORIES,

BY COUNTRY, 2022–2030 (USD MILLION)               172

TABLE 88              AI IN CLINICAL TRIALS MARKET FOR HEALTHCARE PROVIDERS,

BY COUNTRY,  2022–2030 (USD MILLION)            173

TABLE 89              RECENT ACQUISITIONS /COLLABORATIONS WITH CONTRACT RESEARCH ORGANIZATIONS 174

TABLE 90              AI IN CLINICAL TRIALS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,

BY COUNTRY, 2022–2030 (USD MILLION)               174

TABLE 91              AI IN CLINICAL TRIALS MARKET FOR MEDICAL DEVICE MANUFACTURERS,

BY COUNTRY, 2022–2030 (USD MILLION)               175

TABLE 92              AI IN CLINICAL TRIALS MARKET, BY REGION, 2022–2030 (USD MILLION)            177

TABLE 93              NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            179

TABLE 94              NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            179

TABLE 95              NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            179

TABLE 96              NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            180

TABLE 97              NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE,

2022–2030 (USD MILLION)            180

TABLE 98              NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            181

TABLE 99              NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            181

TABLE 100            NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)            182

TABLE 101            NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            182

TABLE 102            US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS              183

TABLE 103            US: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)     184

TABLE 104            US: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            184

TABLE 105            US: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)                185

TABLE 106            US: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)            185

TABLE 107            US: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              186

TABLE 108            US: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            186

TABLE 109            US: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)   187

TABLE 110            US: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)                187

TABLE 111            CANADA: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            188

TABLE 112            CANADA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            188

TABLE 113            CANADA: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            189

TABLE 114            CANADA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)             189

TABLE 115            CANADA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            190

TABLE 116            CANADA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            190

TABLE 117            CANADA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)            191

TABLE 118            CANADA: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            191

TABLE 119            EUROPE: AI IN CLINICAL TRIALS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            193

TABLE 120            EUROPE: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            193

TABLE 121            EUROPE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            194

TABLE 122            EUROPE: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            194

TABLE 123            EUROPE: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)             195

TABLE 124            EUROPE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            195

TABLE 125            EUROPE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            196

TABLE 126            EUROPE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)          196

TABLE 127            EUROPE: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            197

TABLE 128            UK: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)     198

TABLE 129            UK: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            198

TABLE 130            UK: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)                199

TABLE 131            UK: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)            199

TABLE 132            UK: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              200

TABLE 133            UK: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            200

TABLE 134            UK: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)   201

TABLE 135            UK: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)                201

TABLE 136            GERMANY: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            202

TABLE 137            GERMANY: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            203

TABLE 138            GERMANY: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)          203

TABLE 139            GERMANY: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)             204

TABLE 140            GERMANY: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            204

TABLE 141            GERMANY: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            205

TABLE 142            GERMANY: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)            205

TABLE 143            GERMANY: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            206

TABLE 144            FRANCE: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            207

TABLE 145            FRANCE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            207

TABLE 146            FRANCE: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            208

TABLE 147            FRANCE: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)             208

TABLE 148            FRANCE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            209

TABLE 149            FRANCE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            209

TABLE 150            FRANCE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)            210

TABLE 151            FRANCE: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            210

TABLE 152            ITALY: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)     211

TABLE 153            ITALY: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            211

TABLE 154            ITALY: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)                212

TABLE 155            ITALY: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)             212

TABLE 156            ITALY: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            213

TABLE 157            ITALY: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            213

TABLE 158            ITALY: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)   214

TABLE 159            ITALY: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)                214

TABLE 160            SPAIN: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)     215

TABLE 161            SPAIN: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            215

TABLE 162            SPAIN: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            216

TABLE 163            SPAIN: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)             216

TABLE 164            SPAIN: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            217

TABLE 165            SPAIN: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            217

TABLE 166            SPAIN: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)   218

TABLE 167            SPAIN: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)                218

TABLE 168            REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            219

TABLE 169            REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,  2022–2030 (USD MILLION)                 219

TABLE 170            REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            220

TABLE 171            REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY PHASE,

2022–2030 (USD MILLION)            220

TABLE 172            REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            221

TABLE 173            REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            221

TABLE 174            REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)            222

TABLE 175            REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            222

TABLE 176            ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            224

TABLE 177            ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            225

TABLE 178            ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            225

TABLE 179            ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            226

TABLE 180            ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY PHASE,

2022–2030 (USD MILLION)            226

TABLE 181            ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            227

TABLE 182            ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            227

TABLE 183            ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)            228

TABLE 184            ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            228

TABLE 185            JAPAN: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)     229

TABLE 186            JAPAN: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            230

TABLE 187            JAPAN: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            230

TABLE 188            JAPAN: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)             231

TABLE 189            JAPAN: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            231

TABLE 190            JAPAN: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            232

TABLE 191            JAPAN: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)   232

TABLE 192            JAPAN: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)                233

TABLE 193            CHINA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)     234

TABLE 194            CHINA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            234

TABLE 195            CHINA: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            235

TABLE 196            CHINA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)             235

TABLE 197            CHINA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            236

TABLE 198            CHINA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            236

TABLE 199            CHINA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)   237

TABLE 200            CHINA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)                237

TABLE 201            INDIA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION)     238

TABLE 202            INDIA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            238

TABLE 203            INDIA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION)                239

TABLE 204            INDIA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)             239

TABLE 205            INDIA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            240

TABLE 206            INDIA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            240

TABLE 207            INDIA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION)   241

TABLE 208            INDIA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION)                241

TABLE 209            REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            242

TABLE 210            REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,  2022–2030 (USD MILLION)                 242

TABLE 211            REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            243

TABLE 212            REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY PHASE,

2022–2030 (USD MILLION)            243

TABLE 213            REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            244

TABLE 214            REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            244

TABLE 215            REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)            245

TABLE 216            REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            245

TABLE 217            LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            247

TABLE 218            LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            247

TABLE 219            LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            248

TABLE 220            LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            248

TABLE 221            LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE,

2022–2030 (USD MILLION)            249

TABLE 222            LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            249

TABLE 223            LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            250

TABLE 224            LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)            250

TABLE 225            LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            251

TABLE 226            BRAZIL: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            252

TABLE 227            BRAZIL: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            252

TABLE 228            BRAZIL: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            253

TABLE 229            BRAZIL: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)             253

TABLE 230            BRAZIL: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            254

TABLE 231            BRAZIL: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            254

TABLE 232            BRAZIL: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)            255

TABLE 233            BRAZIL: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            255

TABLE 234            MEXICO: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            256

TABLE 235            MEXICO: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            257

TABLE 236            MEXICO: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            257

TABLE 237            MEXICO: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION)             258

TABLE 238            MEXICO: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            258

TABLE 239            MEXICO: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            259

TABLE 240            MEXICO: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)            259

TABLE 241            MEXICO: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            260

TABLE 242            REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            260

TABLE 243            REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,  2022–2030 (USD MILLION)            261

TABLE 244            REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            261

TABLE 245            REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE,

2022–2030 (USD MILLION)            262

TABLE 246            REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,  2022–2030 (USD MILLION)                 262

TABLE 247            REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,  2022–2030 (USD MILLION)                 263

TABLE 248            REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)            263

TABLE 249            REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            264

TABLE 250            MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY REGION,

2022–2030 (USD MILLION)            265

TABLE 251            MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            265

TABLE 252            MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,  2022–2030 (USD MILLION)                 266

TABLE 253            MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            266

TABLE 254            MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY PHASE,

2022–2030 (USD MILLION)            267

TABLE 255            MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            267

TABLE 256            MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            268

TABLE 257            MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)            268

TABLE 258            MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            269

TABLE 259            GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY OFFERING,

2022–2030 (USD MILLION)            270

TABLE 260            GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2022–2030 (USD MILLION)            270

TABLE 261            GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY INDICATION,

2022–2030 (USD MILLION)            271

TABLE 262            GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY PHASE,

2022–2030 (USD MILLION)            271

TABLE 263            GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            272

TABLE 264            GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            272

TABLE 265            GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,

2022–2030 (USD MILLION)            273

TABLE 266            GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY END USER,

2022–2030 (USD MILLION)            273

TABLE 267            REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET,

BY OFFERING,  2022–2030 (USD MILLION)           274

TABLE 268            REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET,

BY DEPLOYMENT MODE, 2022–2030 (USD MILLION)        275

TABLE 269            REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET,

BY INDICATION,  2022–2030 (USD MILLION)       275

TABLE 270            REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET,

BY PHASE,  2022–2030 (USD MILLION)   276

TABLE 271            REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET,

BY APPLICATION, 2022–2030 (USD MILLION)       276

TABLE 272            REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET,

BY TECHNOLOGY, 2022–2030 (USD MILLION)     277

TABLE 273            REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,  2022–2030 (USD MILLION)            277

TABLE 274            REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY END USER,  2022–2030 (USD MILLION)            278

TABLE 275            OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AI IN CLINICAL

TRIALS MARKET               280

TABLE 276            AI IN CLINICAL TRIALS MARKET: DEGREE OF COMPETITION 282

TABLE 277            AI IN CLINICAL TRIALS MARKET: REGION FOOTPRINT       288

TABLE 278            AI IN CLINICAL TRIALS MARKET: OFFERING FOOTPRINT       289

TABLE 279            AI IN CLINICAL TRIALS MARKET: FUNCTION FOOTPRINT       290

TABLE 280            AI IN CLINICAL TRIALS MARKET: END-USER FOOTPRINT       291

TABLE 281            AI IN CLINICAL TRIALS MARKET: DETAILED LIST OF KEY STARTUPS/SMES   294

TABLE 282            AI IN CLINICAL TRIALS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS                 295

TABLE 283            AI IN CLINICAL TRIALS MARKET: PRODUCT/SERVICE/SOLUTION LAUNCHES,  JANUARY 2021–NOVEMBER 2024               298

TABLE 284            AI IN CLINICAL TRIALS MARKET: DEALS, JANUARY 2021– NOVEMBER 2024                299

TABLE 285            AI IN CLINICAL TRIALS MARKET: OTHER DEVELOPMENTS,

JANUARY 2021–  NOVEMBER 2024             300

TABLE 286            IQVIA INC.: COMPANY OVERVIEW            301

TABLE 287            IQVIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED             303

TABLE 288            IQVIA INC.: SOLUTION LAUNCHES, JANUARY 2021–NOVEMBER 2024    303

TABLE 289            IQVIA INC.: DEALS, JANUARY 2021–NOVEMBER 2024        304

TABLE 290            DASSAULT SYSTÈMES (MEDIDATA): COMPANY OVERVIEW          306

TABLE 291            DASSAULT SYSTÈMES (MEDIDATA): PRODUCTS/SERVICES/SOLUTIONS OFFERED    307

TABLE 292            DASSAULT SYSTÈMES (MEDIDATA): SOLUTION LAUNCHES,

JANUARY 2021– NOVEMBER 2024                307

TABLE 293            DASSAULT SYSTÈMES (MEDIDATA): DEALS, JANUARY 2021–NOVEMBER 2024                 308

TABLE 294            INSILICO MEDICINE: COMPANY OVERVIEW                 309

TABLE 295            INSILICO MEDICINE: PRODUCTS/SERVICES/SOLUTIONS OFFERED    309

TABLE 296            INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024                 310

TABLE 297            TEMPUS AI, INC.: COMPANY OVERVIEW                 312

TABLE 298            TEMPUS AI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    312

TABLE 299            TEMPUS AI, INC.: SOLUTION LAUNCHES, JANUARY 2021–NOVEMBER 2024                 313

TABLE 300            TEMPUS AI, INC.: DEALS, JANUARY 2021–NOVEMBER 2024               313

TABLE 301            TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024                 315

TABLE 302            NVIDIA CORPORATION: COMPANY OVERVIEW                 316

TABLE 303            NVIDIA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED    317

TABLE 304            NVIDIA CORPORATION: PRODUCT AND SERVICE LAUNCHES, JANUARY 2021– NOVEMBER 2024    318

TABLE 305            NVIDIA CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024               319

TABLE 306            SAAMA: COMPANY OVERVIEW  322

TABLE 307            SAAMA: PRODUCTS/SERVICES/SOLUTIONS OFFERED             322

TABLE 308            SAAMA: SOLUTION LAUNCHES, JANUARY 2021−NOVEMBER 2024  323

TABLE 309            SAAMA.: DEALS, JANUARY 2021−NOVEMBER 2024        324

TABLE 310            PHESI: COMPANY OVERVIEW     325

TABLE 311            PHESI: PRODUCTS/SERVICES/SOLUTIONS OFFERED             325

TABLE 312            PHESI: SOLUTION LAUNCHES, JANUARY 2021−NOVEMBER 2024  326

TABLE 313            PHESI: DEALS, JANUARY 2021–NOVEMBER 2024                 327

TABLE 314            PATHAI, INC.: COMPANY OVERVIEW      328

TABLE 315            PATHAI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    328

TABLE 316            UNLEARN.AI, INC.: COMPANY OVERVIEW                 329

TABLE 317            UNLEARN.AI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    329

TABLE 318            UNLEARN.AI, INC.: SOLUTION LAUNCHES, JANUARY 2021−NOVEMBER 2024               331

TABLE 319            UNLEARN.AI, INC.: DEALS, JANUARY 2021−NOVEMBER 2024  331

TABLE 320            UNLEARN.AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024                 332

TABLE 321            DEEP6.AI: COMPANY OVERVIEW               333

TABLE 322            DEEP6.AI: PRODUCTS/SERVICES/SOLUTIONS OFFERED             333

TABLE 323            DEEP6.AI: SOLUTION LAUNCH, JANUARY 2021−NOVEMBER 2024  334

TABLE 324            DEEP6.AI: DEALS, JANUARY 2021−NOVEMBER 2024        334

TABLE 325            MICROSOFT: COMPANY OVERVIEW        335

TABLE 326            MICROSOFT: PRODUCTS/SERVICES/SOLUTIONS OFFERED    337

TABLE 327            MICROSOFT CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024    337

TABLE 328            IBM: COMPANY OVERVIEW         340

TABLE 329            IBM: PRODUCTS/SERVICES/SOLUTIONS OFFERED             341

TABLE 330            IBM: DEALS, JANUARY 2021–NOVEMBER 2024                 342

TABLE 331            CONCERTAI: COMPANY OVERVIEW        343

TABLE 332            CONCERTAI: PRODUCTS/SERVICES/SOLUTIONS OFFERED    343

TABLE 333            CONCERTAI: SOLUTION LAUNCHES, JANUARY 2021−NOVEMBER 2024  344

TABLE 334            CONCERTAI: DEALS, JANUARY 2021− NOVEMBER 2024               344

TABLE 335            CONCERTAI: OTHER DEVELOPMENTS, JANUARY 2021− NOVEMBER 2024              345

TABLE 336            AICURE: COMPANY OVERVIEW 346

TABLE 337            AICURE: PRODUCTS/SERVICES/SOLUTIONS OFFERED             346

TABLE 338            AICURE: SERVICE LAUNCHES, JANUARY 2021−NOVEMBER 2024  347

TABLE 339            AICURE: DEALS, JANUARY 2021–NOVEMBER 2024                 347

TABLE 340            MEDIAN TECHNOLOGIES: COMPANY OVERVIEW          349

TABLE 341            MEDIAN TECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED    350

TABLE 342            LANTERN PHARMA INC.: COMPANY OVERVIEW                 351

TABLE 343            LANTERN PHARMA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    351

TABLE 344            LANTERN PHARMA INC.: DEALS, JANUARY 2021−NOVEMBER 2024  352

TABLE 345            CITELINE, A NORSTELLA COMPANY: COMPANY OVERVIEW          353

TABLE 346            CITELINE, A NORSTELLA COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED    353

TABLE 347            CITELINE, A NORSTELLA COMPANY: SOLUTION LAUNCHES, JANUARY 2021− NOVEMBER 2024    354

TABLE 348            CITELINE, A NORSTELLA COMPANY: DEALS, JANUARY 2021–NOVEMBER 2024                 354

TABLE 349            TRINETX, LLC: COMPANY OVERVIEW    355

TABLE 350            TRINETX, LLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED    355

TABLE 351            TRINETX, LLC: DEALS, JANUARY 2021−NOVEMBER 2024  356

TABLE 352            REVIVEMED INC.: COMPANY OVERVIEW                 357

TABLE 353            EURETOS: COMPANY OVERVIEW              358

TABLE 354            VERISIM LIFE: COMPANY OVERVIEW      359

TABLE 355            TRIOMICS: COMPANY OVERVIEW            359

TABLE 356            ARDIGEN: COMPANY OVERVIEW              360

TABLE 357            QUANTHEALTH LTD.: COMPANY OVERVIEW                 361

TABLE 358            DEEP GENOMICS: COMPANY OVERVIEW                 362

LIST OF FIGURES

FIGURE 1              AI IN CLINICAL TRIALS MARKET: SEGMENTS CONSIDERED    34

FIGURE 2              AI IN CLINICAL TRIALS MARKET: YEARS CONSIDERED    37

FIGURE 3              AI IN CLINICAL TRIALS MARKET: RESEARCH DESIGN                39

FIGURE 4              AI IN CLINICAL TRIALS MARKET: KEY DATA FROM SECONDARY SOURCES    41

FIGURE 5              AI IN CLINICAL TRIALS MARKET: KEY PRIMARY SOURCES             42

FIGURE 6              AI IN CLINICAL TRIALS MARKET: KEY DATA FROM PRIMARY SOURCES            43

FIGURE 7              AI IN CLINICAL TRIALS MARKET: KEY INSIGHTS FROM PRIMARIES             44

FIGURE 8              BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION                44

FIGURE 9              MARKET SIZE ESTIMATION: SUPPLY-SIDE REVENUE SHARE ANALYSIS         45

FIGURE 10            AI IN CLINICAL TRIALS MARKET: TOP-DOWN APPROACH         46

FIGURE 11            AI IN CLINICAL TRIALS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF

DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES                 47

FIGURE 12            CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 48

FIGURE 13            AI IN CLINICAL TRIALS MARKET: DATA TRIANGULATION             49

FIGURE 14            AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2024 VS. 2030 (USD MILLION)      52

FIGURE 15            AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2024 VS. 2030 (USD MILLION)      53

FIGURE 16            AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE,

2024 VS. 2030 (USD MILLION)      53

FIGURE 17            AI IN CLINICAL TRIALS MARKET, BY PHASE, 2024 VS. 2030 (USD MILLION)                54

FIGURE 18            AI IN CLINICAL TRIALS MARKET, BY APPLICATION,  2024 VS. 2030 (USD MILLION)    55

FIGURE 19            AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY,  2024 VS. 2030 (USD MILLION)  56

FIGURE 20            AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2024 VS. 2030 (USD MILLION)          56

FIGURE 21            AI IN CLINICAL TRIALS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)      57

FIGURE 22            AI IN CLINICAL TRIALS MARKET: REGIONAL SNAPSHOT          58

FIGURE 23            NEED FOR DATA STANDARDIZATION AND FAVORABLE GOVERNMENT

POLICIES TO DRIVE MARKET     59

FIGURE 24            NORTH AMERICA TO DOMINATE AI IN CLINICAL TRIALS MARKET DURING FORECAST PERIOD                 60

FIGURE 25            US AND PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023                 61

FIGURE 26            UK TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD               62

FIGURE 27            DEVELOPED MARKETS TO REGISTER HIGHER GROWTH RATES

FROM 2024 TO 2029          63

FIGURE 28            AI IN CLINICAL TRIALS MARKET: DRIVERS, RESTRAINTS,

OPPORTUNITIES, AND CHALLENGES     64

FIGURE 29            APPROVAL OF PERSONALIZED MEDICINES BY US FDA, 2015–2023             66

FIGURE 30            HEALTHCARE SECURITY BREACHES OF 500+ RECORDS (2009–2023)     70

FIGURE 31            AI IN CLINICAL TRIALS MARKET: ECOSYSTEM ANALYSIS            75

FIGURE 32            AI IN CLINICAL TRIALS MARKET: VALUE CHAIN ANALYSIS            77

FIGURE 33            AI IN CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES ANALYSIS           79

FIGURE 34            INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR

TOP THREE END USERS              82

FIGURE 35            KEY BUYING CRITERIA FOR TOP THREE END USERS   83

FIGURE 36            PATENT PUBLICATION TRENDS IN AI IN CLINICAL TRIALS MARKET, 2015–2024     87

FIGURE 37            TOP APPLICANTS/OWNERS OF PATENTS AND NUMBER OF PATENTS GRANTED, JANUARY 2015–NOVEMBER 2024        88

FIGURE 38            AI IN CLINICAL TRIALS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS         93

FIGURE 39            AI IN CLINICAL TRIALS MARKET: FUNDING AND NUMBER OF DEALS, 2022–2024   95

FIGURE 40            IMPACT OF AI/GEN AI ON AI-BASED CLINICAL TRIAL SOLUTIONS          96

FIGURE 41            IMPACT OF GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS              98

FIGURE 42            NORTH AMERICA: AI IN CLINICAL TRIALS MARKET SNAPSHOT       178

FIGURE 43            ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET SNAPSHOT          224

FIGURE 44            REVENUE ANALYSIS OF KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET,  2019–2023 (USD BILLION) 281

FIGURE 45            MARKET SHARE ANALYSIS IN AI IN CLINICAL TRIALS MARKET (2023)  282

FIGURE 46            RANKING OF KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET (2023)  284

FIGURE 47            AI IN CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2023       286

FIGURE 48            AI IN CLINICAL TRIALS MARKET: COMPANY FOOTPRINT       287

FIGURE 49            AI IN CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 293

FIGURE 50            EV/EBITDA OF KEY VENDORS   296

FIGURE 51            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF

AI IN CLINICAL TRIAL KEY VENDORS   296

FIGURE 52            AI IN CLINICAL TRIALS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS     297

FIGURE 53            IQVIA INC.: COMPANY SNAPSHOT           302

FIGURE 54            DASSAULT SYSTÈMES (MEDIDATA): COMPANY SNAPSHOT          306

FIGURE 55            NVIDIA CORPORATION: COMPANY SNAPSHOT                 317

FIGURE 56            MICROSOFT: COMPANY SNAPSHOT        336

FIGURE 57            IBM: COMPANY SNAPSHOT         341

FIGURE 58            MEDIAN TECHNOLOGIES: COMPANY SNAPSHOT          349

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 精密林業市場規模、シェア、動向、2030年までの世界予測 2025-11-05
• フィールドサービス管理市場規模、シェア、動向、2030年までの世界予測 2025-11-05
• 採血装置市場規模、シェア、動向、2030年までの世界予測 2025-11-04
• 車載半導体市場規模、シェア、動向、2030年までの世界予測 2025-11-04
• データセンターUPS市場規模、シェア、動向、2030年までの世界予測 2025-10-31

MarketsandMarkets  出版レポート一覧